Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DYN vs APLS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

APLS Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

APLS Overall Winner 6-Pillar Tally: DYN 0 – 6 APLS Matrix Metrics: DYN 0 – 10 APLS

As of Nov 20, 2026, Apellis Pharmaceuticals, Inc. (APLS) is the stronger overall head-to-head candidate over Dyne Therapeutics, Inc. (DYN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DYN carries a Unified Composite Score of 39.9/100 (SELL) at $15.50 (N/M Forward P/E, 0.0% operating margin), whereas APLS carries 60.2/100 (BUY) at $41.03 (46.3x Forward P/E, 9.9% operating margin).

  • Technical & Structure Timing Caution: DYN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0); meanwhile APLS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DYN vs APLS
DYN NASDAQ
Dyne Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$15.50
-3.31% 1D
Market Cap $3.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.55β · 55% Vol
Unified Composite Score
39.9 / 100 SELL
Tech 25.0 Fund 48.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.0%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $17.08 · SMA50: $16.55
APLS NASDAQ Head-to-Head Winner
Apellis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$41.03
-0.07% 1D
Market Cap $5.3B
TTM Revenue $1.11B
Forward P/E 46.3x
Beta / 30D Vol 4.54β · 2% Vol
Unified Composite Score
60.2 / 100 BUY
Tech 40.0 Fund 52.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (30.4% over 20 days), RSI 84
RSI-14: 84.5 · SMA20: $40.97 · SMA50: $32.36

6-Pillar Scorecard Institutional Category Breakdown (DYN 0 – 6 APLS)

Columns: Metric · DYN · APLS
1. Valuation Multiples APLS
Forward P/E N/M 46.3x
Trailing P/E N/M 38.3x
PEG Ratio 0.19x N/M
EV / Revenue N/M 4.8x
2. Growth & Scale APLS
Revenue Growth (YoY) +0.0% +60.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $1.11B
Market Cap $3.0B $5.3B
3. Profitability & Quality APLS
Gross Margin N/A 64.3%
Operating Margin 0.0% 9.9%
Net Profit Margin 0.0% 12.1%
Return on Equity (ROE) -74.6% 46.0%
4. Balance Sheet & Cash Flow APLS
Cash Generation (TTM) -$569M $167M EBITDA
Cash Flow Margin N/A 15.1% EBITDA Mgn
Net Cash / Leverage $694M Net Cash $3.24 Book/Sh · 46.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning APLS
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 58.2% (9th %ile) 0.3% (<1st %ile)
Put/Call OI Skew 0.06x (Call-Skewed) 0.89x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat APLS
OpEx & R&D Intensity N/A 54.4% of Rev ($601M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DYN (0) vs APLS (10)
Institutional Metric DYN APLS Criterion Row Edge
Market Capitalization
Scale
$3.0B $5.3B Larger Scale APLS
Trailing P/E Ratio
Valuation
N/M 38.3x Lower Multiple APLS
Forward P/E Ratio
Valuation
N/M 46.3x Lower Multiple APLS
Revenue Growth (YoY)
Growth
+0.0% +60.9% Higher Growth APLS
Operating Margin (TTM)
Profitability
0.0% 9.9% Higher Margin APLS
Net Profit Margin
Profitability
0.0% 12.1% Higher Margin APLS
Return on Equity (ROE)
Capital Efficiency
-74.6% 46.0% Higher ROE APLS
52-Week Range Position
Momentum
11% ($14–$27) 100% ($16–$41) Stronger Trend APLS
Beta / 30D Volatility
Risk Regime
1.55β · 55% Vol 4.54β · 2% Vol Lower Realized Risk APLS
Unified Institutional Score
Composite Signal
39.9 / 100 (SELL) 60.2 / 100 (BUY) Higher Composite APLS
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.11B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 64.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.19x PEG · N/M EV/Rev N/M PEG · 4.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$569M ($694M Net Cash) $167M EBITDA ($3.24 Book/Sh · 46.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon APLS +7.36 pp
DYN: -6.92% · APLS: +0.44%
3M Horizon APLS +73.36 pp
DYN: +10.55% · APLS: +83.91%
6M Horizon APLS +121.44 pp
DYN: -10.49% · APLS: +110.95%
1Y Horizon APLS +121.44 pp
DYN: -10.49% · APLS: +110.95%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DYN vs APLS. Trailing 12-month operating profitability (DYN 0.0% vs APLS 9.9%) and valuation multiples (DYN N/M vs APLS 46.3x Forward P/E) are benchmarked directly in Pillar 4 below.

DYN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-74.6% · N/M
APLS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.11B
Gross Margin64.3%
Op. Margin9.9%
ROE / Fwd P/E46.0% · 46.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DYN BREAKDOWN
72d in phase · OBV DISTRIBUTION
Current IV 58.2%
IV Percentile 9th %ile
Put/Call OI Skew 0.06x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact DYN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
APLS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.3%
IV Percentile <1st %ile
Put/Call OI Skew 0.89x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact APLS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $15.87 · IV 56.7%

DYN Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,587)

Compare $1,587 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 56.7% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $16 / $17.5 Bull Call Spread

Buy 2x $16C · Sell 2x $17.5C · 30d

Net Entry $200 Debit
T+5d @ +5% Move +$24 (+12%)
Max Risk / Buffer $200 Capped
5d Edge & Liquidity 0.5x R:R · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $16 / $15 Bear Put Spread

Buy 2x $16P · Sell 2x $15P · 30d

Net Entry $136 Debit
T+5d @ -5% Drop +$22 (+16%)
Max Risk / Buffer $136 Capped
5d Edge & Liquidity 0.6x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DYN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
APLS Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $5.3B market capitalization and 9.9% operating margin.
OpEx & R&D Reinvestment 54.4% of Rev ($601M)
90D Engineering Disclosures 0 Published

Investor FAQ DYN vs APLS Key Questions & Quantitative Answers

As of Nov 20, 2026, Apellis Pharmaceuticals, Inc. (APLS) is the stronger overall head-to-head candidate over Dyne Therapeutics, Inc. (DYN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DYN carries a Unified Composite Score of 39.9/100 (SELL) at $15.50 (N/M Forward P/E, 0.0% operating margin), whereas APLS carries 60.2/100 (BUY) at $41.03 (46.3x Forward P/E, 9.9% operating margin). Technical & Structure Timing Caution: DYN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0); meanwhile APLS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

APLS leads the Growth & Scale pillar: DYN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with APLS at +60.9% YoY revenue growth and +0.0% YoY earnings growth on $1.11B TTM revenue (64.3% gross margin, 9.9% operating margin). On trailing 12-month operating scale, DYN generates N/A in USD-normalized revenue versus $1.11B for APLS. In operating R&D and SG&A reinvestment, DYN deploys N/A (0 90-day corporate R&D disclosures) versus 54.4% of Rev ($601M) (0 disclosures) for APLS.

APLS screens cheaper on headline valuation multiples. DYN trades at N/M Forward P/E, N/M Trailing P/E, 0.19x PEG, and N/M EV/Revenue (unreported FCF margin), whereas APLS trades at 46.3x Forward P/E, 38.3x Trailing P/E, N/M PEG, and 4.8x EV/Revenue (15.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DYN (-74.6% ROE) versus APLS (46.0% ROE) capital efficiency.

In options market volatility and institutional positioning, DYN carries 58.2% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.55β · 55% Vol realized risk). By comparison, APLS carries 0.3% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.89x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.54β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.